Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Cohort Studies
Cyclophosphamide
/ pharmacology
Epirubicin
/ pharmacology
Female
Filgrastim
/ pharmacology
Fluorouracil
/ pharmacology
Humans
Male
Middle Aged
Neoadjuvant Therapy
/ methods
Polyethylene Glycols
/ pharmacology
Retrospective Studies
FEC-100
Pegfilgrastim
breast cancer
febrile neutropenia
relative dose intensity
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
01
12
2019
revised:
13
12
2019
accepted:
18
12
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
20
3
2020
Statut:
ppublish
Résumé
This study aimed was to clarify the impact of pegfilgrastim (PEG) 3.6 mg primary prophylaxis of febrile neutropenia (FN) on the average relative dose intensity (ARDI) of neoadjuvant/adjuvant FEC-100 for breast cancer. This retrospective, single-centre cohort study including 296 patients who received FEC-100 compared PEG and non-PEG groups. The PEG group received PEG 3.6 mg as a single subcutaneous injection in each study cycle. The primary endpoint was the ARDI of FEC-100. The secondary endpoints were patient percentage of ARDI≥85%, factors associated with ARDI≥85%, and reasons for reduced ARDI. The PEG group showed significantly higher mean ARDI (95.6% versus 90.7%, p<0.001) and patient percentage of ARDI≥85% (93.0% versus 79.9%, p=0.001). PEG was significantly associated with ARDI≥85% (p=0.009). Neutropenia and FN, the main reasons for reduced ARDI, were significantly lower in the PEG group (p<0.05). Primary PEG 3.6 mg prophylaxis increased the ARDI of FEC-100.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
This study aimed was to clarify the impact of pegfilgrastim (PEG) 3.6 mg primary prophylaxis of febrile neutropenia (FN) on the average relative dose intensity (ARDI) of neoadjuvant/adjuvant FEC-100 for breast cancer.
MATERIALS AND METHODS
METHODS
This retrospective, single-centre cohort study including 296 patients who received FEC-100 compared PEG and non-PEG groups. The PEG group received PEG 3.6 mg as a single subcutaneous injection in each study cycle. The primary endpoint was the ARDI of FEC-100. The secondary endpoints were patient percentage of ARDI≥85%, factors associated with ARDI≥85%, and reasons for reduced ARDI.
RESULTS
RESULTS
The PEG group showed significantly higher mean ARDI (95.6% versus 90.7%, p<0.001) and patient percentage of ARDI≥85% (93.0% versus 79.9%, p=0.001). PEG was significantly associated with ARDI≥85% (p=0.009). Neutropenia and FN, the main reasons for reduced ARDI, were significantly lower in the PEG group (p<0.05).
CONCLUSION
CONCLUSIONS
Primary PEG 3.6 mg prophylaxis increased the ARDI of FEC-100.
Identifiants
pubmed: 32014935
pii: 40/2/915
doi: 10.21873/anticanres.14024
doi:
Substances chimiques
pegfilgrastim
3A58010674
Polyethylene Glycols
3WJQ0SDW1A
Epirubicin
3Z8479ZZ5X
Cyclophosphamide
8N3DW7272P
Filgrastim
PVI5M0M1GW
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
915-921Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.